Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns (Children ' Adults)- Protocol MW2008-09-03
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Bromelains (Primary)
- Indications Burns
- Focus Adverse reactions
- Sponsors MediWound
- 09 Feb 2017 According to a MediWound media release, data from this phase II (PK) study and PK data in large burns obtained from the ongoing DETECT study will intend to support a request to FDA and EMA to extend the label for NexoBrid (Bromelains) to larger burns.
- 06 Apr 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 26 May 2014 New trial record